US Patent Number
Compositions containing PBN, or active derivatives thereof, in a suitable pharmaceutical carrier for administration to a patient, are disclosed for treating or preventing gastric ulceration caused by ingestion of non-steroidal anti-inflammatories. Based on animal studies, the dosage is in the range of 3 to 300 mg/kg and is administered prior to, simultaneously, or shortly after ingestion of the NSAID compounds(s). In the preferred embodiment, the range is between 10 and 30 mg/kg, depending on the dosage unit required to protect the mucosa. The preferred method of administration is orally, alone or in combination with the non-steroidal anti-inflammatory. It is believed that the PBN is also useful alone for treatment or prevention of ulcers, aspects of diarrhea, gastritis, esophagitis, ileitis, and as an analgesic.
Oklahoma Medical Research Foundation, Oklahoma City, Okla., University of Kentucky Research Foundation, Lexington, Ky.
Carney, John M. and Floyd, Robert A., "Phenylbutyl Nitrone Compositions and Methods for Prevention of Gastric Ulceration" (1996). Pharmacology and Nutritional Sciences Faculty Patents. 48.